{"id":"NCT01683071","sponsor":"Pacira Pharmaceuticals, Inc","briefTitle":"Femoral Nerve Block With Liposome Bupivacaine for Postsurgical Analgesia Following Total Knee Arthroplasty","officialTitle":"A Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Dose Ranging Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Single Injection Femoral Nerve Block With Liposome Bupivacaine for Postsurgical Analgesia in Subjects Undergoing Total Knee Arthroplasty","status":"COMPLETED","phase":"PHASE2","dates":{"start":"2012-09","primaryCompletion":"2013-12","completion":"2013-12","firstPosted":"2012-09-11","resultsPosted":"2020-12-09","lastUpdate":"2020-12-09"},"enrollment":297,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"TREATMENT"},"conditions":["Postoperative Pain"],"interventions":[{"type":"DRUG","name":"Placebo","otherNames":["Preservative-free normal saline."]},{"type":"DRUG","name":"EXPAREL 67 mg","otherNames":["Bupivacaine liposome injectable suspension 67 mg/5 mL"]},{"type":"DRUG","name":"EXPAREL 133 mg","otherNames":["Bupivacaine liposome injectable suspension 133 mg/10 mL"]},{"type":"DRUG","name":"EXPAREL 266 mg","otherNames":["Bupivacaine liposome injectable suspension 266 mg/20 mL"]}],"arms":[{"label":"(Part 1) EXPAREL 67 mg","type":"EXPERIMENTAL"},{"label":"(Part 1) EXPAREL 133 mg","type":"EXPERIMENTAL"},{"label":"(Part 1) EXPAREL 266 mg","type":"EXPERIMENTAL"},{"label":"(Part 1) Placebo","type":"PLACEBO_COMPARATOR"},{"label":"(Part 2) EXPAREL 266 mg","type":"EXPERIMENTAL"},{"label":"(Part 2) Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The primary objectives of Part 1 are to (1) evaluate three dose levels of liposome bupivacaine versus placebo with respect to the magnitude and duration of the analgesic effect achieved following single dose injection femoral nerve block with liposome bupivacaine, and (2) select a single therapeutic dose of liposome bupivacaine from the three dose levels to be tested in Part 2.\n\nPart 2: The primary objective of Part 2 is to compare the magnitude and duration of the analgesic effect of single injection femoral nerve block of a single dose level of liposome bupivacaine (selected from Part 1) with placebo (preservative-free normal saline).","primaryOutcome":{"measure":"Area Under the Curve (AUC) of Numeric Rating Scale at Rest (NRS-R) Pain Intensity Scores Through 72 Hours","timeFrame":"0-72 hours","effectByArm":[{"arm":"(Part 1) EXPAREL 67 mg","deltaMin":533.4,"sd":33.15},{"arm":"(Part 1) EXPAREL 133 mg","deltaMin":427.2,"sd":31.73},{"arm":"(Part 1) EXPAREL 266 mg","deltaMin":436.2,"sd":31.79},{"arm":"(Part 1) Placebo","deltaMin":530.5,"sd":31.73},{"arm":"(Part 2) EXPAREL 266 mg","deltaMin":418.9,"sd":16.86},{"arm":"(Part 2) Placebo","deltaMin":515.5,"sd":16.95}],"pValues":[{"comp":"OG000 vs OG003","p":"0.9494"},{"comp":"OG001 vs OG003","p":"0.0237"},{"comp":"OG002 vs OG003","p":"0.0386"},{"comp":"OG004 vs OG005","p":"<0.0001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":30,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":4,"n":22},"commonTop":["Nausea","Pyrexia","Constipation","Pruritis","Vomiting"]}}